Inquirer Technology on MSN4d
US approves 1st fast-acting insulin biosimilar for diabetes
The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls ...
The Cardiology Advisor6d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
MPR14d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
optometryadvisor15d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. HealthDay News — ...
Renal & Urology News18d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
Merilog administered subcutaneously 5 to 10 minutes before mealtime helps improve glycemic control. (HealthDay News) — The US Food and Drug Administration has approved Merilog (insulin-aspart ...
WebMD18d
FDA OKs First Fast-Acting Insulin Biosimilar for Diabetes
Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to Novo Nordisk’s Novolog) that helps control blood sugar spikes when taken five to 10 minutes before a meal.
Medical Xpress19d
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
Saipan Tribune19d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...
news.bloomberglaw19d
California Insulin Program Remains Over a Year Away to Market
The rollout of California’s program to develop low-cost copycat versions of insulin, known as biosimilars, remains more than a year away from distribution, a top official told state lawmakers ...
Managed Healthcare Executive20d
FDA Approves First Biosimilar of Novolog
The FDA has approved Sanofi’s Merilog (insulin-aspart-szjj ... assistance Programs across our therapeutic areas. Novo Nordisk’s NovoLog has a list prices of $139.71 for FlexPen, $72.34 for 10 mL vial, ...